News & Events about Oramed Pharmaceuticals Inc.
Oramed Announces Top-line Results from Phase 3 Trial of ORMD-0801 for the Treatment of Type 2 Diabetes Oramed Announces Top-line Results from Phase 3 Trial of ORMD-0801 for the Treatment of Type 2 Diabetes PR Newswire NEW YORK, Jan. 11, 2023 NEW YORK, Jan. 11, 2023 /PRNewswire/ -- Oramed...
Oramed Granted U.S. Combination Therapy Patent for Oral GLP-1 & Insulin for the Treatment of Diabetes Oramed Granted U.S. Combination Therapy Patent for Oral GLP-1 & Insulin for the Treatment of Diabetes PR Newswire NEW YORK, Jan. 4, 2023 NEW YORK, Jan. 4, 2023 /PRNewswire/ --Oramed...
Oramed Letter to Shareholders Oramed Letter to Shareholders PR Newswire NEW YORK, Dec. 21, 2022 Topline Pivotal Phase 3 Oral Insulin Data Expected Mid-January 2023Phase 2 NASH Trial Achieved Primary and Secondary EndpointsDefinitive Deal Signed to Commercialize Oral Insulin in South Korea $160...
Oramed Announces Additional Positive Safety and Efficacy Data from Its Phase 2 Clinical Trial of ORMD-0801 for NASH Oramed Announces Additional Positive Safety and Efficacy Data from Its Phase 2 Clinical Trial of ORMD-0801 for NASH PR Newswire NEW YORK, Nov. 17, 2022 Achieved primary endpoint of...
Oramed Subsidiary Oravax Reports Positive Preliminary Phase 1 Data for its Oral Covid-19 Vaccine Oramed Subsidiary Oravax Reports Positive Preliminary Phase 1 Data for its Oral Covid-19 Vaccine PR Newswire NEW YORK, Oct. 7, 2022 Primary and secondary endpoints of safety and immunogenicity met Oral...